SmofKabiven/SmofKabiven Peripheral

Per 1,000 mL SmofKabiven Amino acids 51 g, nitrogen 8 g, Na 41 mmol, K 30 mmol, Mg 5.1 mmol, Ca 2.5 mmol, phosphate 13 mmol, Zn 0.04 mmol, sulphate 5.1 mmol, Cl 36 mmol, acetate 106 mmol, glucose (anhydrous) 127 g, lipids 38 g. Total Energy: 1,100 kCal/986 mL; 1,600 kCal/1,477 mL; 2,200 kCal/1,970 mL. Osmolality: Approx 1,800 mOsmol/kg·H₂O. Osmolarity: Approx 1,500 mOsmol/L. Per 1,448 mL SmofKabiven Peripheral Glucose (anhydrous) 103 g, amino acids 46 g, nitrogen 7.4 g, lipids 41 g, Na 36 mmol, K 28 mmol, Mg 4.6 mmol, Ca 2.3 mmol, phosphate 11.9 mmol, Zn 0.03 mmol, sulphate 4.6 mmol, Cl 32 mmol, acetate 96 mmol. Total energy: Approx 1,000 kCal. Osmolality: Approx 950 mOsmol/kg water. Osmolarity: Approx 850 mOsmol/L. Per 1,904 mL SmofKabiven Peripheral Glucose (anhydrous) 135 g, amino acids 60 g, nitrogen 9.8 g, lipids 54 g, Na 48 mmol, K 36 mmol, Mg 6 mmol, Ca 3 mmol, phosphate 15.6 mmol, Zn 0.05 mmol, sulphate 6.1 mmol, Cl 42 mmol, acetate 125 mmol. Total energy: Approx 1,300 kCal. Osmolality: Approx 950 mOsmol/kg water. Osmolarity: Approx 850 mOsmol/L

Parenteral nutrition for adults (& childn ≥2 yr for SmofKabiven) when oral or enteral nutrition is impossible, insufficient or contraindicated.

SmofKabiven IV Administer via infusion into a central vein over 14-24 hr in adult & adolescent & 12-24 hr in childn. Individualized dosage. Adult & adolescent Range: 13-31 mL/kg daily. Max dose: 35 mL/kg daily. Max infusion rate: 2 mL/kg/hr. Childn 2-11 yr Up to 35 mL/kg daily, regularly adjusted depending on patient requirement. Max dose: 35 mL/kg daily. Max infusion rate: 2.4 mL/kg/hr. SmofKabiven Peripheral IV Administer via infusion into peripheral or central vein over 14-24 hr. Adult Individualised dosage. Range: 20-40 mL/kg daily. Max dose: 40 mL/kg daily. Max infusion rate: 3 mL/kg/hr.

Hypersensitivity to fish, egg, soya or peanut protein. Severe hyperlipidemia, liver insufficiency & blood coagulation disorders; congenital errors of amino acid metabolism; acute shock; uncontrolled hyperglycaemia; pathologically elevated serum levels of any of included electrolytes; acute pulmonary oedema, hyperhydration, decompensated cardiac insufficiency; hemophagocytic syndrome; unstable conditions eg, severe post-traumatic conditions, uncompensated DM, acute MI, stroke, embolism, metabolic acidosis, severe sepsis, hypotonic dehydration & hyperosmolar coma. Severe renal insufficiency w/o access to hemofiltration or dialysis. Infant & childn <2 yr.

Cross allergic reactions between soya-bean & peanut. Stop infusion if any abnormal sign in electrolytes occurs. Interrupt infusion if sign or symptom of anaphylactic reaction occurs. Not to be given simultaneously w/ blood in the same infusion set. Not to exceed 4 mmol/L serum triglyceride conc during infusion. Fat overload syndrome w/ overdose. Impaired lipid metabolism in patients w/ renal failure, DM, pancreatitis, impaired liver function, hypothyroidism & sepsis. Lactic acidosis, insufficient cellular O₂ supply & increased serum osmolarity. Increased risk of infection. Increased urinary excretion of trace elements, particularly Cu & Zn. Patients w/ tendency towards electrolyte retention. Malnourished; hyperglycaemic patients. Monitor capacity to eliminate fat by checking triglyceride levels; serum glucose, electrolytes & osmolarity, fluid balance, acid-base status & liver enzyme tests; blood cell count & coagulation; serum levels. Correct electrolyte & fluid balance disturbances prior to infusion. Control phosphate & K intake in patients w/ renal insufficiency. May interfere w/ lab measurements eg, bilirubin, LDH, O₂ saturation, Hb. Not suitable for use in newborns or infants <2 yr. SmofKabiven: Hemodialysis patients. Childn 2-16 or 18 yr. SmofKabiven Peripheral: Evaluate daily for local signs of thrombophlebitis. Childn 2-11 yr.

Slight increase in body temp.

Parenteral Nutritional Products

V06DE - Amino acids/carbohydrates/minerals/vitamins, combinations ; Used as general nutrients.

D